Lido Advisors
VKTX icon

Lido Advisors’s Viking Therapeutics VKTX Stock Holding History

Lido Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
+5,781
New +$187K ﹤0.01% 1905
2026
Q1 		– Sell
-20,986
Closed -$619K – 2141
2025
Q4 		$619K Sell
20,986
-857
-4% -$30.4K ﹤0.01% 1214
2025
Q3 		$574K Buy
+21,843
New +$652K ﹤0.01% 1183

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Lido Advisors's VKTX Position: Q2 2026 in Review

Lido Advisors opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 5,781 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #1905 among its holdings. This is a return to the name: Lido Advisors previously reported a position in VKTX as recently as Q4 2025.

Lido Advisors first reported a position in VKTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $619K in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Lido Advisors held 5,781 shares of Viking Therapeutics worth $226K as of Q2 2026.
  • Viking Therapeutics was a new Lido Advisors position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1905 holding.
  • Lido Advisors first reported a position in Viking Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Lido Advisors's Viking Therapeutics position peaked at $619K in Q4 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.